[{"id":"0c84ebb7-7fc4-41b0-89f2-110ac246df29","acronym":"","url":"https://clinicaltrials.gov/study/NCT02249949","created_at":"2021-01-23T05:52:29.927Z","updated_at":"2024-07-02T16:35:46.246Z","phase":"Phase 2","brief_title":"Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02249949","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" DDIT3","pipe":"","alterations":" ","tags":["DDIT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e efatutazone (CS-7017)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 10/04/2018","primary_completion_date":" 10/04/2018","study_txt":" Completion: 05/01/2023","study_completion_date":" 05/01/2023","last_update_posted":"2023-06-07"},{"id":"e2b3b219-7316-4420-a622-46f70d51a11e","acronym":"METOXY-LACC","url":"https://clinicaltrials.gov/study/NCT04275713","created_at":"2021-01-18T20:45:57.367Z","updated_at":"2024-07-02T16:36:11.040Z","phase":"Phase 2","brief_title":"Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC","source_id_and_acronym":"NCT04275713 - METOXY-LACC","lead_sponsor":"Oslo University Hospital","biomarkers":" DDIT3 • ERO1A • STC2","pipe":"","alterations":" ","tags":["DDIT3 • ERO1A • STC2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 05/22/2020","start_date":" 05/22/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2022-05-03"}]